
EquitySector - HealthcareVery High Risk
Regular
NAV (09-Oct-26)
Returns (Since Inception)
Fund Size
₹428 Cr
Expense Ratio
3.12%
ISIN
INF966L01CG3
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
18 Jul 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.53%
+12.33% (Cat Avg.)
3 Years
+18.23%
+19.98% (Cat Avg.)
Since Inception
+18.77%
— (Cat Avg.)
| Equity | ₹423.93 Cr | 98.98% |
| Others | ₹4.36 Cr | 1.02% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Nca-Net Current Assets | Cash | ₹-116.53 Cr | 27.21% |
| Treps 01-Sep-2026 Depo 10 | Cash - Repurchase Agreement | ₹97.04 Cr | 22.66% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹45.31 Cr | 10.58% |
| Future on Glenmark Pharmaceuticals Ltd | Equity - Future | ₹42.09 Cr | 9.83% |
| Future on Divi's Laboratories Ltd | Equity - Future | ₹40.52 Cr | 9.46% |
| Zydus Lifesciences Ltd | Equity | ₹39.82 Cr | 9.30% |
| Pfizer Ltd | Equity | ₹37.81 Cr | 8.83% |
| Alivus Life Sciences Ltd | Equity | ₹34.62 Cr | 8.08% |
| Future on Torrent Pharmaceuticals Ltd | Equity - Future | ₹33.69 Cr | 7.87% |
| Concord Biotech Ltd | Equity | ₹30.13 Cr | 7.03% |
| SMS Pharmaceuticals Ltd | Equity | ₹28.73 Cr | 6.71% |
| Ipca Laboratories Ltd | Equity | ₹26.63 Cr | 6.22% |
| Zydus Wellness Ltd | Equity | ₹24.18 Cr | 5.64% |
| Aurobindo Pharma Ltd | Equity | ₹22.18 Cr | 5.18% |
| Strides Pharma Science Ltd | Equity | ₹10.48 Cr | 2.45% |
| Future on Aurobindo Pharma Ltd | Equity - Future | ₹6.42 Cr | 1.50% |
| India (Republic of) | Bond - Short-term Government Bills | ₹3 Cr | 0.70% |
| India (Republic of) | Bond - Short-term Government Bills | ₹3 Cr | 0.70% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.99 Cr | 0.70% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.98 Cr | 0.70% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.98 Cr | 0.70% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.97 Cr | 0.69% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.97 Cr | 0.69% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.96 Cr | 0.69% |
| Sumitomo Chemical India Ltd Ordinary Shares | Equity | ₹1.32 Cr | 0.31% |
Large Cap Stocks
7.87%
Mid Cap Stocks
42.60%
Small Cap Stocks
39.05%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹275.71 Cr | 64.37% |
| Consumer Defensive | ₹24.18 Cr | 5.64% |
| Basic Materials | ₹1.32 Cr | 0.31% |
Standard Deviation
This fund
18.33%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
0.69
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better

Since July 2023
Since July 2023
Since July 2023
Since January 2025
Since March 2025
Since February 2025
Since March 2025
ISIN INF966L01CG3 | Expense Ratio 3.12% | Exit Load 1.00% | Fund Size ₹428 Cr | Age 3 years 2 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,06,621 Cr
Address
A.M. Road, Prabhadevi, Mumbai, 400025
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments